Mark S Fineman

Title: The Innovative Contributions of Mark S Fineman in Metabolic Disorder Treatments

Introduction

Mark S Fineman, based in San Diego, California, has made significant strides in the field of pharmaceuticals with a remarkable portfolio of 27 patents to his name. His innovative research primarily focuses on combating metabolic disorders through advanced compositions and methodologies.

Latest Patents

Fineman's latest patents delve into groundbreaking formulations for treating metabolic disorders. One notable patent outlines methods to enhance the gastrointestinal tolerability of biguanide compounds, particularly metformin. This invention aims at patients who may face contraindications for traditional biguanide treatments. By introducing delayed-release formulations targeted at the small intestine, he provides a novel approach to treating conditions such as diabetes and obesity. Another patent further elaborates on methods involving biguanide compositions for treating various metabolic diseases, offering more options for patients suffering from these conditions.

Career Highlights

Throughout his professional journey, Mark S Fineman has collaborated with notable companies such as Elcelyx Therapeutics, Inc. and Amylin Pharmaceuticals, Inc. His efforts in these organizations have significantly advanced the development of therapeutic strategies addressing metabolic disorders.

Collaborations

Fineman has worked alongside esteemed colleagues, including Alain D Baron and Nigel R A Beeley. This collaborative spirit contributes to the shared goal of creating effective treatments and innovations in the pharmaceutical landscape.

Conclusion

Mark S Fineman continues to be a driving force in the realm of metabolic disorder treatment, showcasing an impressive ability to engineer innovative solutions through his extensive patent portfolio. His work not only highlights his inventive prowess but also underscores the critical advancements being made in addressing pressing health issues.